Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 6/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26665267 | 0.98 | KCNA3 (0.57) | KCNA3CTSKEPHX1DRD2BTK | |
| SCHEMBL23421609 | 0.93 | KCNA3 (0.55) | KCNA3CTSKEPHX1DRD2BTK | |
| SCHEMBL913704 | 0.88 | KCNA3 (0.56) | KCNA3CTSKEPHX1DRD2BTK | |
| SCHEMBL913264 | 0.88 | KCNA3 (0.56) | KCNA3CTSKEPHX1DRD2BTK | |
| SCHEMBL916322 | 0.87 | KCNA3 (0.50) | KCNA3CTSKEPHX1DRD2BTK | |
| SCHEMBL916321 | 0.87 | KCNA3 (0.50) | KCNA3CTSKEPHX1DRD2BTK | |
| SCHEMBL12971748 | 0.87 | KCNA3 (0.57) | KCNA3CTSKEPHX1DRD2BTK | |
| SCHEMBL619386 | 0.87 | KCNA3 (0.57) | KCNA3CTSKEPHX1DRD2BTK | |
| SCHEMBL13547360 | 0.86 | KCNA3 (0.52) | KCNA3CTSKEPHX1DRD2BTK | |
| SCHEMBL2515507 | 0.86 | DRD2 (0.63) | KCNA3CTSKEPHX1DRD2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| US-20110015180-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-7858781-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2010-12-28 | — | — | US | disclosed |
| EP-1720859-B1 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20070155721-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-07-05 | — | — | US | disclosed |
| EP-1720859-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077932-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015180-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | KCNA3 2250/4885CTSK 1384/4885EPHX1 406/4885 |
| US-20070155721-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | KCNA3 2172/4885CTSK 1405/4885EPHX1 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.